These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 32930446)

  • 1. Neuropsychological impact of trametinib in pediatric low-grade glioma: A case series.
    Peterson RK; McKeown T; Tabori U; Bartels U; Bouffet E; Janzen L
    Pediatr Blood Cancer; 2020 Dec; 67(12):e28690. PubMed ID: 32930446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma.
    Manoharan N; Choi J; Chordas C; Zimmerman MA; Scully J; Clymer J; Filbin M; Ullrich NJ; Bandopadhayay P; Chi SN; Yeo KK
    J Neurooncol; 2020 Sep; 149(2):253-262. PubMed ID: 32780261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trametinib therapy for children with neurofibromatosis type 1 and life-threatening plexiform neurofibroma or treatment-refractory low-grade glioma.
    Ronsley R; Hounjet CD; Cheng S; Rassekh SR; Duncan WJ; Dunham C; Gardiner J; Ghag A; Ludemann JP; Wensley D; Rehmus W; Sargent MA; Hukin J
    Cancer Med; 2021 Jun; 10(11):3556-3564. PubMed ID: 33939292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to trametinib treatment in progressive pediatric low-grade glioma patients.
    Selt F; van Tilburg CM; Bison B; Sievers P; Harting I; Ecker J; Pajtler KW; Sahm F; Bahr A; Simon M; Jones DTW; Well L; Mautner VF; Capper D; Hernáiz Driever P; Gnekow A; Pfister SM; Witt O; Milde T
    J Neurooncol; 2020 Sep; 149(3):499-510. PubMed ID: 33026636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01.
    Perreault S; Larouche V; Tabori U; Hawkin C; Lippé S; Ellezam B; Décarie JC; Théoret Y; Métras MÉ; Sultan S; Cantin É; Routhier MÈ; Caru M; Legault G; Bouffet É; Lafay-Cousin L; Hukin J; Erker C; Jabado N
    BMC Cancer; 2019 Dec; 19(1):1250. PubMed ID: 31881853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trametinib-associated Hyponatremia in a Child With Low-grade Glioma is Not Seen Following Treatment With Alternative MEK Inhibitor.
    Lazow MA; Lawson SA; Salloum R; Hummel TR; Pillay Smiley N; DeWire-Schottmiller MD; Fouladi M; de Blank P
    J Pediatr Hematol Oncol; 2021 May; 43(4):e550-e553. PubMed ID: 32520842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of trametinib on the neuropsychological profile of NF1 patients.
    Lalancette E; Cantin É; Routhier MÈ; Mailloux C; Bertrand MC; Kiaei DS; Larouche V; Tabori U; Hawkins C; Ellezam B; Décarie JC; Théoret Y; Métras MÉ; McKeown T; Ospina LH; Vairy S; Ramaswamy V; Coltin H; Sultan S; Legault G; Bouffet É; Lafay-Cousin L; Hukin J; Erker C; Caru M; Dehaes M; Jabado N; Perreault S; Lippé S
    J Neurooncol; 2024 May; 167(3):447-454. PubMed ID: 38443693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trametinib for progressive pediatric low-grade gliomas.
    Kondyli M; Larouche V; Saint-Martin C; Ellezam B; Pouliot L; Sinnett D; Legault G; Crevier L; Weil A; Farmer JP; Jabado N; Perreault S
    J Neurooncol; 2018 Nov; 140(2):435-444. PubMed ID: 30097824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recalcitrant trametinib-induced paronychia treated successfully with topical timolol in a pediatric patient.
    Martínez-de-Espronceda I; Bernabeu-Wittel J; Azcona M; Monserrat MT
    Dermatol Ther; 2020 Jan; 33(1):e13164. PubMed ID: 31705590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pneumocephalus in a Pediatric Patient with Glioma Receiving Trametinib.
    Gorsi H; Marupudi NI; Sood S; Altinok D; Yankelevich M
    Pediatr Neurosurg; 2020; 55(1):51-53. PubMed ID: 31661699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trametinib Toxicities in Patients With Low-grade Gliomas and Diabetes Insipidus: Related Findings?
    Egan G; Hamilton J; McKeown T; Bouffet E; Tabori U; Dirks P; Bartels U
    J Pediatr Hematol Oncol; 2020 May; 42(4):e248-e250. PubMed ID: 30676433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trametinib-based Treatment of Pediatric CNS Tumors: A Single Institutional Experience.
    Paul MR; Pehlivan KC; Milburn M; Yeh-Nayre L; Elster J; Crawford JR
    J Pediatr Hematol Oncol; 2020 Nov; 42(8):e730-e737. PubMed ID: 32398601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF/MEK inhibitors use to treat ventriculoperitoneal shunt-associated ascites in pediatric low-grade gliomas.
    Amayiri N; Obeidat M; Laban DA; Musharbash A; Al-Hussaini M; Maraqa B; Ibrahimi A; Sarhan N; Bouffet E
    Pediatr Blood Cancer; 2024 Aug; 71(8):e31058. PubMed ID: 38753385
    [No Abstract]   [Full Text] [Related]  

  • 14. Dabrafenib and trametinib in BRAFV600E mutated glioma.
    Brown NF; Carter T; Kitchen N; Mulholland P
    CNS Oncol; 2017 Oct; 6(4):291-296. PubMed ID: 28984141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic activity of mTORC1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity.
    Arnold A; Yuan M; Price A; Harris L; Eberhart CG; Raabe EH
    Neuro Oncol; 2020 Apr; 22(4):563-574. PubMed ID: 31841591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
    Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dabrafenib Effective in Pediatric Glioma.
    Cancer Discov; 2017 Jan; 7(1):OF5. PubMed ID: 28062673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid Clinical and Radiographic Response With Combined Dabrafenib and Trametinib in Adults With
    Johanns TM; Ferguson CJ; Grierson PM; Dahiya S; Ansstas G
    J Natl Compr Canc Netw; 2018 Jan; 16(1):4-10. PubMed ID: 29295876
    [No Abstract]   [Full Text] [Related]  

  • 19. Improved survival with MEK inhibition in BRAF-mutated melanoma.
    Flaherty KT; Robert C; Hersey P; Nathan P; Garbe C; Milhem M; Demidov LV; Hassel JC; Rutkowski P; Mohr P; Dummer R; Trefzer U; Larkin JM; Utikal J; Dreno B; Nyakas M; Middleton MR; Becker JC; Casey M; Sherman LJ; Wu FS; Ouellet D; Martin AM; Patel K; Schadendorf D;
    N Engl J Med; 2012 Jul; 367(2):107-14. PubMed ID: 22663011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumors.
    Cox DS; Allred A; Zhou Y; Infante JR; Gordon MS; Bendell J; Jones S; Burris H; Orford K
    Clin Pharmacol Drug Dev; 2015 Jul; 4(4):287-94. PubMed ID: 27136909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.